Vigil Neuroscience has secured a $40 million strategic investment from Sanofi, who purchased 537,634 of Vigil’s Series A non-voting preferred shares, convertible to common stock at a price of $7.44 per share. The funds will be used to support Vigil’s R&D activities. Additionally, Vigil has granted Sanofi the right of first negotiation for exclusive rights related to Vigil’s TREM2 agonist program, including the candidate VG-3927, which is in Phase 1 trials for Alzheimer’s Disease. Goodwin’s legal team, comprising several key attorneys, advised Vigil in this transaction.

Biotechnology, Pharmaceuticals,Global, United States